Evidence map›Paper›PMID 29523317›Full record

ArticleTuberculosis (Edinburgh, Scotland)2018

Modeling the structural origins of drug resistance to isoniazid via key mutations in Mycobacterium tuberculosis catalase-peroxidase, KatG.

Matthew W Marney, Robert P Metzger, David Hecht, Faramarz Valafar

Abstract read
In one paragraph

Article in Tuberculosis (Edinburgh, Scotland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Frontiers in microbiology · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Matthew W MarneyDepartment of Chemistry and Biochemistry, San Diego State University, San Diego, CA 92182-1030, USA.
Robert P MetzgerDepartment of Chemistry and Biochemistry, San Diego State University, San Diego, CA 92182-1030, USA.
David HechtDepartment of Chemistry and Biochemistry, San Diego State University, San Diego, CA 92182-1030, USA; Department of Chemistry, Southwestern College, Chula Vista, CA 91910, USA.
Faramarz ValafarBiomedical Informatics Research Center, San Diego State University, San Diego, CA 92182-7720, USA. Electronic address: faramarz@sdsu.edu.

Funding

Evolutionary and Functional Significance of Novel Mutations in MDR-XDR TBR01AI105185 · NIAID · SAN DIEGO STATE UNIVERSITY · PI VALAFAR, FARAMARZ · 2013 to 2021
$5.3M
NIAID NIH HHS R01 AI105185
6 · The paper itself

Abstract

WHO reported 10.4 million new tuberculosis (TB) cases and 1.8 million deaths in 2015, making M. tuberculosis the most successful human pathogen with highest mortality among infectious diseases [1,2]. Drug-resistant TB is a major threat to global TB control [2,3]. Recently Torres et al. [4] identified 14 novel substitutions in M. tuberculosis-KatG (the enzyme associated with resistance to isoniazid-an important first-line anti-TB drug) and demonstrated that 12 of the 14 can cause INH-resistance in M. smegmatis. This study presents an in silico structure-based analysis of these 14 amino acid substitutions using homology models and x-ray crystal structures (when available) in M. tuberculosis. Our models demonstrate that several of these mutations cluster around three openings in the KatG tertiary structure which appear to initiate channels to the heme group at the catalytic center of the enzyme. We studied the effects of these mutations on the tertiary structure of KatG, focusing on conformational changes in the three channels in the protein structure. Our results suggest that the 14 novel mutations sufficiently restrict one or more of these access channels, thus potentially preventing INH from reaching the catalytic heme. These observations provide valuable insights into the structure-based origins of INH resistance and provide testable hypotheses for future experimental studies.

Indexed as

MutationAntitubercular AgentsBacterial ProteinsCatalaseCatalytic DomainCrystallography, X-RayDrug Resistance, BacterialGenotypeIsoniazidMicrobial Sensitivity TestsModels, MolecularMycobacterium tuberculosisPhenotypeProtein Structure, TertiaryStructure-Activity RelationshipAntitubercular AgentsBacterial ProteinsCatalaseIsoniazidkatG protein, Mycobacterium tuberculosis

Identifiers

PMID29523317
PMCPMC7330162

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.